CORRESP Filing
Kairos Pharma, LTD.
Date: April 22, 2025 · CIK: 0001962011 · Accession: 0001641172-25-005650
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286662
Letter
KAIROS PHARMA LTD.
Westwood Blvd., #139
Los Angeles CA 90064
(818) 404-5541
April 22, 2025
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Re: Kairos Pharma, Ltd.
Registration Statement on Form S-1
File No. 333-286662
Acceleration Request
Requested Date: April 24, 2025
Requested Time: 5:00 PM Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Kairos Pharma, Ltd. (the "Registrant") hereby requests acceleration of the effective date of its registration statement on Form S-1 (File No. 333-286662) so that it may become effective at 5:00 p.m. Eastern Time on April 24, 2025, or at such time as the Registrant may request by telephone to the staff (the "Staff") of the Securities and Exchange Commission. In addition, the Registrant hereby authorizes Megan J. Penick, Esq. of Dorsey & Whitney LLP, counsel for the Registrant, to make such request on the Registrant's behalf.
Very
truly yours,
Kairos
Pharma, Ltd.
Show Raw Text
CORRESP 1 filename1.htm KAIROS PHARMA LTD. 2355 Westwood Blvd., #139 Los Angeles CA 90064 (818) 404-5541 April 22, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Kairos Pharma, Ltd. Registration Statement on Form S-1 File No. 333-286662 Acceleration Request Requested Date: April 24, 2025 Requested Time: 5:00 PM Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Kairos Pharma, Ltd. (the "Registrant") hereby requests acceleration of the effective date of its registration statement on Form S-1 (File No. 333-286662) so that it may become effective at 5:00 p.m. Eastern Time on April 24, 2025, or at such time as the Registrant may request by telephone to the staff (the "Staff") of the Securities and Exchange Commission. In addition, the Registrant hereby authorizes Megan J. Penick, Esq. of Dorsey & Whitney LLP, counsel for the Registrant, to make such request on the Registrant's behalf. Very truly yours, Kairos Pharma, Ltd. /s/ John S. Yu Name: John S. Yu Title: Chief Executive Officer and Chairman of the Board of Directors